Clin2
NCT07096869Possibly a fitRecruiting

Breast cancer trial comparing two forms of paclitaxel

Bioequivalence

Treatments studied

Part of Cancer clinical trials.

This study checks if a generic version of paclitaxel protein-bound particles works the same as the brand-name drug in people with breast cancer. It's for patients whose cancer has spread or returned, and who might benefit from this medicine alone.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
28 people
Ages
18 years to 75 years
Study type
Interventional

Who can take part

  • You have breast cancer that has spread or returned after previous treatment.
  • You are between 18 and 75 years old.
  • Your cancer doctor thinks paclitaxel alone is a good option for you.
  • You are in generally good health, with adequate blood cell counts and liver/kidney function.
  • You have not had major surgery in the last 4 weeks, and can avoid pregnancy for at least 6 months.
  • You have no severe allergies to paclitaxel or human albumin.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06354114Not yet recruiting· Phase 2
Study of a new form of paclitaxel for advanced breast cancer

This study tests an experimental version of the chemotherapy drug paclitaxel for people with advanced breast cancer. It may help shrink tumors and slow the cancer's growth.

Harbin, Heilongjiang
NCT04136782Recruiting· Phase 4
Tests two chemo drug combinations for triple-negative breast cancer

This Phase 4 trial compares two chemotherapy combinations to treat stage II–III triple-negative breast cancer. It looks for which regimen works better and is tolerated in people with measurable tumors and good overall health.

Harbin, Heilongjiang
NCT06765590Recruiting
Paclitaxel (albumin-bound) bioequivalence study in breast cancer

This study tests whether a new version of paclitaxel (albumin-bound) works the same as the approved version in people with breast cancer. It's for patients whose cancer has spread or returned after other treatments, or those for whom this drug is recommended by treatment guidelines.

Luoyang, Henan
NCT06199895Recruiting· Phase 2
Study of paclitaxel for patients with taxane-resistant solid tumors

This trial tests paclitaxel given as tiny micelle particles for people whose cancer (pancreatic, bile duct, lung, stomach, esophagus, or breast) stopped responding to taxane chemotherapy or did not shrink. The goal is to see if this treatment can help when standard taxanes no longer work.

Wuhan, Hubei
NCT06752811Recruiting· Phase 3
Testing a new paclitaxel formula for advanced pancreatic cancer

This trial tests a new form of the chemotherapy drug paclitaxel (called polymeric micellar paclitaxel) for people with pancreatic cancer that has spread to other parts of the body (metastatic). It's for those who haven't had any prior treatment for their metastatic cancer, and aims to see if this drug can help control the cancer.

Nanjing, Jiangsu
NCT05287308Not yet recruiting
Comparing two chemotherapies after breast cancer surgery

This trial is comparing two types of chemotherapy (standard taxane vs a newer albumin-bound paclitaxel) given after surgery to see which is better at preventing breast cancer from returning. It is for women with HER2-negative breast cancer that has a high risk of coming back.

Beijing, Beijing Municipality

Hear when a new Bioequivalence trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.